Abbott Laboratories (ABT)
NYSE: ABT · IEX Real-Time Price · USD
113.66
+0.18 (0.16%)
At close: Mar 28, 2024, 4:00 PM
113.50
-0.16 (-0.14%)
After-hours: Mar 28, 2024, 7:55 PM EDT
Abbott Laboratories Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Abbott Laboratories stock have an average target of 125.27, with a low estimate of 107 and a high estimate of 141. The average target predicts an increase of 10.21% from the current stock price of 113.66.
Analyst Consensus: Buy
* Price targets were last updated on Feb 14, 2024.
Analyst Ratings
The average analyst rating for ABT stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 4 | 4 |
Buy | 10 | 10 | 7 | 6 | 5 | 5 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 20 | 20 | 16 | 15 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Reiterates $128 | Buy | Reiterates | $128 | +12.62% | Feb 14, 2024 |
Barclays | Barclays | Buy Maintains $133 → $141 | Buy | Maintains | $133 → $141 | +24.05% | Jan 26, 2024 |
Citigroup | Citigroup | Strong Buy Maintains $123 → $126 | Strong Buy | Maintains | $123 → $126 | +10.86% | Jan 25, 2024 |
RBC Capital | RBC Capital | Buy Reiterates $128 | Buy | Reiterates | $128 | +12.62% | Jan 25, 2024 |
Raymond James | Raymond James | Buy Maintains $124 → $127 | Buy | Maintains | $124 → $127 | +11.74% | Jan 25, 2024 |
Financial Forecast
Revenue This Year
42.43B
from 40.11B
Increased by 5.79%
Revenue Next Year
45.50B
from 42.43B
Increased by 7.23%
EPS This Year
4.64
from 3.26
Increased by 42.30%
EPS Next Year
5.16
from 4.64
Increased by 11.29%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 44.7B | 48.0B | 51.9B | 54.2B | 58.2B |
Avg | 42.4B | 45.5B | 48.8B | 50.6B | 56.0B |
Low | 40.9B | 43.7B | 46.5B | 47.4B | 54.3B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 11.3% | 13.2% | 14.1% | 11.0% | 15.0% |
Avg | 5.8% | 7.2% | 7.3% | 3.7% | 10.6% |
Low | 2.0% | 3.0% | 2.2% | -2.8% | 7.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 4.94 | 5.63 | 6.32 | 6.87 | 7.68 |
Avg | 4.64 | 5.16 | 5.75 | 6.10 | 7.38 |
Low | 3.92 | 4.30 | 5.42 | 5.42 | 7.16 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 51.4% | 21.3% | 22.4% | 19.4% | 25.8% |
Avg | 42.3% | 11.3% | 11.4% | 6.1% | 21.0% |
Low | 20.2% | -7.3% | 5.0% | -5.8% | 17.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.